Last 12 months
Inside the activity.
0 purchase rows · 64 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 34 |
| Jan 2026 | 0 | 21 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock | 25,000 | $4.20 | $105,000.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 6 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock | 15,000 | $5.19 | $77,850.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 5 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock | 10,000 | $2.62 | $26,200.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 4 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock | 15,000 | $2.19 | $32,850.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock | 5,000 | $2.01 | $10,050.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock | 7,000 | $4.75 | $33,250.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 22:48 UTC |
PERRY MICHAEL SDirector
|
SaleCommon Stock | 6,100 | $36.42 | $222,162.00 |
DisclosureSEC source: 0001209191-20-028978 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| May 12, 2020 Filed May 13, 2020 22:48 UTC |
PERRY MICHAEL SDirector
|
SaleCommon Stock | 29,900 | $35.71 | $1,067,729.00 |
DisclosureSEC source: 0001209191-20-028978 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.35 to $36.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:45 UTC |
Waddill William D.Director
|
SaleCommon Stock | 26,000 | $36.54 | $950,040.00 |
DisclosureSEC source: 0001209191-20-028975 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 213 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · derivative · entry 21 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,347 Underlying: Common Stock · 213 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 830 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · derivative · entry 20 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,560 Underlying: Common Stock · 830 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · derivative · entry 19 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,390 Underlying: Common Stock · 1,200 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,454 | $0.00 Strike: $14.54 | $0.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · derivative · entry 18 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,590 Underlying: Common Stock · 1,454 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · derivative · entry 17 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,044 Underlying: Common Stock · 500 shares Expires 2025-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 700 | $40.00 | $28,000.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 15 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,730 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 204 | $40.00 | $8,160.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 14 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,430 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 213 | $40.00 | $8,520.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 13 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,634 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 830 | $40.00 | $33,200.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 12 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,847 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 1,200 | $40.00 | $48,000.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 11 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,677 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 1,454 | $40.00 | $58,160.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 10 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,877 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 500 | $40.00 | $20,000.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 9 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,331 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 213 | $5.20 | $1,107.60 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 8 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 830 | $5.19 | $4,307.70 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 7 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 1,200 | $4.75 | $5,700.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 6 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 1,454 | $14.54 | $21,141.16 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 5 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 500 | $7.75 | $3,875.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 4 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 200 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · derivative · entry 16 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,544 Underlying: Common Stock · 200 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 100 | $40.00 | $4,000.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 3 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,634 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 200 | $40.00 | $8,000.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,734 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:19 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 200 | $5.19 | $1,038.00 |
DisclosureSEC source: 0001209191-20-026230 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $14.54 | $0.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · derivative · entry 14 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,744 Underlying: Common Stock · 5,300 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,456 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · derivative · entry 13 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,044 Underlying: Common Stock · 3,456 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,700 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · derivative · entry 12 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,500 Underlying: Common Stock · 3,700 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,800 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · derivative · entry 11 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,200 Underlying: Common Stock · 3,800 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 3,805 | $40.00 | $152,200.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 10 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,734 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 3,454 | $40.00 | $138,160.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 9 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,539 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 5,300 | $40.00 | $212,000.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 8 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858,993 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4 Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 3,456 | $40.00 | $138,240.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 7 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,293 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 3,700 | $40.00 | $148,000.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 6 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,749 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4 Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 3,800 | $40.00 | $152,000.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 5 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,449 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 5,300 | $14.54 | $77,062.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 4 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 3,456 | $5.20 | $17,971.20 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 3 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 3,700 | $5.19 | $19,203.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:00 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 3,800 | $4.75 | $18,050.00 |
DisclosureSEC source: 0001209191-20-025382 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2020 Filed Jun 24, 2020 22:10 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $35.40 | $17,700.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 7 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 23:47 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 1,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024687 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,813 Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 23:47 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 25,000 | $36.89 | $922,250.00 |
DisclosureSEC source: 0001209191-20-024687 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,925 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.63 to $37.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 16, 2020 Filed Jun 24, 2020 22:10 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $23.94 | $11,970.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 6 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Read SEC document |
| March 12, 2020 Filed Jun 24, 2020 22:10 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $24.80 | $12,400.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 5 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| March 11, 2020 Filed Jun 24, 2020 22:10 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $28.60 | $14,300.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 4 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.